Agasti 2021: I-FDA inikeze i-axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) imvume esheshayo ezigulini ezikhulile ezine-lymphoma ephindaphindekayo noma e-refractory follicular lymphoma (FL) ngemva kwemigqa emibili noma ngaphezulu yokwelashwa kwe-systemic. Ingoma..